For this purpose, we performed next-generation sequencing in several human cell lines and employed genetic tumor mouse models with intestine- and mammary-specific deletions of Usp22. Finally, after identifying HSP90AB1 as a novel USP22-dependent target gene, we evaluated the therapeutic targetability of USP22-deficient tumor cells in vitro and in vivo. This evidence concerns the gene USP22 and neoplasm.